Loading…

Apotea ABAPOTEA.STCompetitor analysis, valuation and peers

Sweden · SEK·Consumer Discretionary›Specialty Stores
Momentum leader 94
Mkt cap
$1.04B
US dollars, full cap
Free float
51%
of shares outstanding
$/day
$3.46M
20-day average traded
Fwd P/E
34.8×
forward earnings
ROIC−WACC
+16.1 pp
WACC 5.0%
Hurdle
-4 pp
Req g minus delivered
Next earnings
78 days
4 Feb 2027
Close · SEKSEK 101.30
1D+0.1%
1W-0.4%
1M+13.4%
3M+36.6%
6M+30.4%
YTD+9.8%
1Y+15.2%
ATR %2.8%
52w lowhigh5.5% off high

What Apotea does

Employees: 969

Apotea at a glance

Size Apotea (APOTEA.ST) is a Sweden Consumer Discretionary company (Specialty Stores) with a market value of $1.04B, the 129th largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 101.30 on 18 Nov 2026.

Performance Over six months the shares gained 30.4%, against +4.5% for the median peer and +2.8% for the Sweden market (cap-weighted) — 3rd highest of 20 in its peer set.

Growth Revenue grew 10.2% over the last twelve months (peer median +6.3%); the operating margin is 4.1% (peer median 5.9%).

Valuation It trades at 34.8× forward earnings against a peer median of 15.2× (3rd most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 16.1 points above its cost of capital (5.0% WACC).

Next results Next results expected around 4 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026APOTEA.ST 131Peer median 105
Six months, rebased to 100: Apotea against the median of its 20 peers (local-currency closes).

Apotea financials

Reported figures in SEK; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
RevenueSEK 7.81BSEK 7.20BSEK 6.54BSEK 5.45B
Revenue growth—+10%+20%—
Gross profitSEK 323MSEK 302MSEK 257MSEK 97.4M
EBITDASEK 536MSEK 459MSEK 384MSEK 216M
Net incomeSEK 259MSEK 229MSEK 215MSEK 87.0M
Free cash flowSEK 134MSEK 120MSEK 43.4MSEK 95.9M
Capital expenditureSEK 19.0MSEK 216MSEK 164MSEK 121M
Total debtSEK 263MSEK 331MSEK 242MSEK 262M

Quarterly statements and history in the cockpit →

Apotea competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%PET01169690600335301078BLUESTONE000026257720PNGJLHZO3186SYNSAM002818LNFBILI-AAPOTEA.ST6-month return →1-month return →
Up and to the right = strong over both horizons. Apotea is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%0×100×200×300×PET01169690301078BLUESTONE000026257720PNGJLHZO3186002818DOUAPOTEA.STRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Apotea is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%PET9690600335301078000026257720HZORUSTA3186SYNSAMEYEAPOTEA.STGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Apotea is the large dot.

Apotea competitors and peer comparison

How Apotea compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Apotea against its 20 peers (data as of 18 Nov 2026)
MeasureAPOTEA.STPeer medianRank in peer set
1-month return+13.4%-1.6%3rd highest of 21
6-month return+30.4%+4.5%3rd highest of 20
Distance from 52-week high-5.5%-24.9%2nd highest of 21
Revenue growth (TTM)+10.2%+6.3%8th highest of 21
Operating margin4.1%5.9%7th lowest of 20
Forward P/E34.8×15.2×3rd most expensive of 19
Growth the price implies (Req g, 7 yrs)6.2%-2.4%4th most demanding of 17
Growth delivered (Del g)+10.2%+5.1%5th highest of 17
Hurdle (Req g minus delivered)-4.1 pp-7.4 pp5th most demanding of 17
ROIC minus cost of capital+16.1 pp+4.2 pp2nd highest of 19
EV / EBITDA20.0×7.2×2nd most expensive of 13
Net debt / EBITDA0.3×2.1×6th least indebted of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Apotea APOTEA.STSweden$1.04B+30%+10%4%34.8×6.2%+10.2%
Pet Valu PET.TOCanada$1.06B+26%+5%16%13.2×-2.8%+12.6%
Chow Sang Sang Holdings International 0116.HKHong Kong$1.08B+14%+16%20%2.9×n/an/a
TUHU Car 9690.HKHong Kong$1.09B-17%+16%0%20.4×-19.3%+12.7%
Sinomach Automobile 600335.SSChina$1.09B-18%-11%2%n/a-11.7%-4.2%
Kidswant Digital Technology 301078.SZChina$1.14B-27%+5%5%20.1×-2.0%+4.2%
Bluestone Jewellery and Lifestyle BLUESTONE.NSIndia$1.14B+51%+38%9%311.2×n/an/a
FIYTA Precision Technology 000026.SZChina$1.16B+5%+2%n/a58.5×7.3%-3.8%
SILICON 2 257720.KSSouth Korea$1.17B-42%+50%18%7.5×-19.0%+62.2%
P N Gadgil Jewellers PNGJL.NSIndia$921M+12%+51%6%15.8×n/an/a
MarineMax HZOUnited States$1.19B+57%-6%2%32.4×24.8%+1.0%
Rusta RUSTA.STSweden$1.19B-20%+8%8%17.9×2.3%+7.3%
Nextage 3186.TJapan$1.20B-30%+24%4%10.9×-0.1%+22.0%
Augmont Enterprises AUGMONT.NSIndia$901Mn/a+42%0%n/an/an/a
Synsam SYNSAM.STSweden$880M+14%+9%10%16.5×-3.6%+10.2%
CEWE Stiftung & Co. KGaA CWC.DEGermany$879M+9%+4%11%10.3×-4.3%+3.5%
Chengdu Fusen Noble-House Industrial 002818.SZChina$1.23B-4%-22%42%11.0×-3.0%-1.0%
Douglas DOU.DEGermany$874M-13%+1%4%6.2×-1.5%+7.6%
Leon's Furniture LNF.TOCanada$1.31B+13%-1%8%12.2×-4.3%+3.0%
Bilia BILI-A.STSweden$1.32B+4%+1%3%14.6×1.2%+6.0%
National Vision EYEUnited States$1.37B+5%+7%5%16.2×11.3%+3.0%

Questions

Which companies are Apotea's closest peers?
The cockpit's peer set: Pet Valu (PET.TO), Chow Sang Sang Holdings International (0116.HK), TUHU Car (9690.HK), Sinomach Automobile (600335.SS), Kidswant Digital Technology (301078.SZ), Bluestone Jewellery and Lifestyle (BLUESTONE.NS), FIYTA Precision Technology (000026.SZ), SILICON 2 (257720.KS).
Is Apotea expensive compared with its peers?
On forward p/e it trades at 34.8× against a peer median of 15.2×, 3rd most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Apotea stock performed?
Over six months to 18 Nov 2026 the shares returned +30.4% against +4.5% for the median peer; over one year +15.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.